ClinicalTrials.gg
RecruitingNCT06767813Updated Sep 19, 2025

Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms

A Phase 2 interventional study of TQB2868 injection and Gemcitabine injection in Pancreatic Neoplasms, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.. Recruiting at 7 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-09-19.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Mar 2024, registered Jan 2025).
  • Started Mar 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 630 studies in Pancreatic Neoplasms with a site in China — 334 open to participants now, 359 under way, 30 of them phase 3. Pancreatic Neoplasms · China.

Planned enrollment
196th of 508
80 · median 58
Started
2024
with 107 others
Phase 2
155 of 630
89 open now
Primary completion
2026-11
later than 175 of 358 live
Registered
477th of 630
by date

Among the 630 studies in Pancreatic Neoplasms with a site in China, this one is the 196th largest by planned enrollment of the 508 interventional ones that give a count, is one of 108 that started in 2024, is one of 155 in phase 2, reaches primary completion later than 175 of the 358 other live ones, and was the 477th registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,002 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

334 of the 630 studies in Pancreatic Neoplasms with a site in China are open now. Recruiting first, the newest first:

329 more — sign in →

All 334 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 742 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 630 studies in Pancreatic Neoplasms with a site in China, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of TQB2868 injection combined with anlotinib capsule and chemotherapy in treated patients with Pancreatic Neoplasms

03

Conditions studied

  • Pancreatic Neoplasms
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must voluntarily participate in the study and sign the form.
  • Aged between 18 and 75 years (inclusive) at the time of signing the informed consent form.
  • Diagnosed with pancreatic ductal adenocarcinoma through histological or cytological confirmation.
  • Have at least one evaluable lesion according to 1.1 criteria;
  • No prior systemic anti-tumor therapy (including but not limited to chemotherapy, radiotherapy, targeted therapy, or immunotherapy). Patients who experience disease progression more than 6 months after completing or adjuvant therapy are eligible.
  • (ECOG) performance status of 0-1, with an expected survival of more than 3 months.
  • Normal major organ function.
  • Patients must use reliable during the study period and for 6 months after the end of the study period; Female participants must have a negative serum or urine pregnancy test within 7 days prior to enrollment and must not be breastfeeding.

Exclusion criteria

Exclusion Criteria:

  • Subjects with a history of or concurrent diagnosis of other malignant tumors within the past 5 years.
  • Unresolved toxicities from prior treatments exceeding Grade 1 according to Common Terminology Criteria (CTC) AE criteria, excluding alopecia.
  • Major surgical procedures, significant traumatic injuries, or unhealed wounds or fractures within 28 days prior to the first dose.
  • Any bleeding or hemorrhagic event of ≥ Grade 3 according to CTC AE criteria within 4 weeks prior to the first dose.
  • Arterial or venous thrombotic events within 6 months prior to the first dose.
  • Active gastric or duodenal ulcers, perforations, persistent positive fecal occult blood tests, ulcerative colitis, or other gastrointestinal bleeding conditions within 6 months prior to the first dose; or other bleeding conditions as assessed by the investigator.
  • virus (HBV)-infected patients unable to adhere to consistent antiviral therapy, or virus (HCV)-infected patients (positive for HCV Ab or HCV RNA) deemed unstable by the investigator or requiring continued antiviral therapy without consistent adherence.
  • History of substance abuse involving psychotropic drugs that cannot be discontinued or presence of psychiatric disorders.
  • Symptomatic interstitial lung disease or conditions likely to cause drug-induced lung toxicity or related pneumonitis.
  • Presence of any severe and/or uncontrolled diseases.
  • Histological or cytological confirmation of other pathological types, such as acinar cell carcinoma, neuroendocrine carcinoma, or pancreatoblastoma.
  • Tumors confirmed via imaging (CT or MRI) to have invaded major blood vessels, with the investigator deeming a high likelihood of fatal hemorrhage during the study.
  • Tumors confirmed via imaging (CT or MRI) to have invaded the gastrointestinal tract, with a high risk of bleeding based on endoscopy and investigator assessment.
  • Known central nervous system and/or carcinomatous meningitis.
  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage, as assessed by the investigator.
  • History of severe allergic reactions to biologic agents or known to any component of TQB2868 injection.
  • Chronic treatment with systemic or other agents within 28 days prior to the first dose, and continued use of such medications within 2 weeks after the first dose.
  • Receipt of within 28 days prior to the first dose or planned administration of live attenuated vaccines during the study.
  • Systemic therapy required within 2 years prior to the first dose for any condition. Alternative therapies are not considered systemic therapy.
  • Participation in other clinical trials involving anti-tumor drugs within 28 days prior to the first dose.
  • Any comorbidities or conditions deemed by the investigator to pose severe risks to the subject's safety or the completion of the study, or any other reasons rendering the subject unsuitable for enrollment.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    TQB2868 injection+Gemcitabine injection+ Albumin paclitaxel injection+ Anlotinib capsules

    Treatment period: TQB2868 injection combined with Gemcitabine injection and Albumin paclitaxel injection, 28 days as a treatment cycle. Oral administration of Anlotinib capsules tablets once a day, for 2 weeks followed by a 1 week untreated recovery phase. Maintenance period: TQB2868 injection combined with Gemcitabine injection, 21 days as a treatment cycle. Oral administration of Anlotinib capsules tablets once a day, for 2 weeks followed by a 1 week untreated recovery phase.

    Drug: TQB2868 injection · Drug: Gemcitabine injection · Drug: Albumin paclitaxel injection · Drug: Anlotinib capsules

  • Experimental
    TQB2868 injection+Gemcitabine injection +Albumin paclitaxel injection

    Treatment period TQB2868 injection combined with Gemcitabine injection and Albumin paclitaxel injection, 28 days as a treatment cycle. Maintenance period TQB2868 injection combined with Gemcitabine injection, 21 days as a treatment cycle.

    Drug: TQB2868 injection · Drug: Gemcitabine injection · Drug: Albumin paclitaxel injection

Interventions

  • TQB2868 injection is an anti-PD 1/growth factor (GF)-β Receptor Type II (TGF-βRII) bifunctional fusion protein.

  • Gemcitabine injection

  • DrugAlbumin paclitaxel injection

    Albumin paclitaxel injection

  • Anlotinib capsules

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    The time between the start of treatment and tumorigenesis (in any aspect) progression or death (due to any cause). The evaluation was based on the date of first dose, and efficacy was evaluated every 8 weeks (56±7 days).

    Time frame: The evaluation was based on the date of first dose, and efficacy was evaluated every 8 weeks (56±7 days)

Secondary outcomes

  1. Objective Response Rate (ORR)

    The proportion of patients whose tumors have shrunk to a prespecified value and are able to maintain the minimum time limit is the sum of the proportion of complete and partial responses.

    Time frame: The evaluation was based on the date of first dose, and efficacy was evaluated every 8 weeks (56±7 days)

  2. Overall survival (OS)

    Time from the start of treatment to death (due to any cause).

    Time frame: The evaluation was based on the date of first dose, and efficacy was evaluated every 8 weeks (56±7 days)

  3. Duration of Response (DOR)

    The period between the first diagnosis of CR or PR and the discovery of progressive disease (PD).

    Time frame: The evaluation was based on the date of first dose, and efficacy was evaluated every 8 weeks (56±7 days)

  4. Disease Control Rate (DCR)

    The percentage of cases with remission (PR+CR) and stable lesion (SD) after treatment accounted for the number of evaluable cases.

    Time frame: The evaluation was based on the date of first dose, and efficacy was evaluated every 8 weeks (56±7 days)

  5. Incidence and severity of adverse events (AEs)

    The occurrence of all adverse events.

    Time frame: The evaluation was based on the date of first dose, and efficacy was evaluated every 8 weeks (56±7 days)

  6. Peak concentration (Cmax)

    Maximum plasma drug concentration.

    Time frame: Day1-7 of cycle1 and cycle 4 : 0 hour pre-dose, 0,1, 2, 4, 8, 24, 48, 72, 144 hours after dose. Cycle1 Day15: 0 hour pre-dose. Day1 of cycle2 and 3 : 0 hour pre-dose. 0 hour after dose, Cycle4 Day15: 0 hour pre-dose. 28days as a cycle.

  7. Transforming growth factor-beta (TGF-β)

    The relationship between TGF - β content in plasma and anti-tumor efficacy.

    Time frame: Before first dose, 30 minutes after the first dose, pre-dose at Cycle 2 Day 1, pre-dose at the first efficacy assessment, pre-dose at the time of remission at the first efficacy evaluation, and at the time of progression, each cycle is 28 days.

  8. Incidence of immunogenicity (ADA)

    Incidence of immunogenicity (ADA).

    Time frame: Cycle1, 2, 4, 8: Before injection. 30 and 90 days after the last dose

  9. Time to maximum blood concentration (Tmax)

    Time to maximum blood concentration.

    Time frame: Day1-7 of cycle1 and cycle 4 : 0 hour pre-dose, 0,1, 2, 4, 8, 24, 48, 72, 144 hours after dose. Cycle1 Day15: 0 hour pre-dose. Day1 of cycle2 and 3 : 0 hour pre-dose. 0 hour after dose, Cycle4 Day15: 0 hour pre-dose. 28days as a cycle.

  10. Area under the time-concentration curve (AUC0-t)

    Area under the time-concentration curve, 0-t hours after administration.

    Time frame: Day1-7 of cycle1 and cycle 4 : 0 hour pre-dose, 0,1, 2, 4, 8, 24, 48, 72, 144 hours after dose. Cycle1 Day15: 0 hour pre-dose. Day1 of cycle2 and 3 : 0 hour pre-dose. 0 hour after dose, Cycle4 Day15: 0 hour pre-dose. 28days as a cycle.

  11. The area under the time-concentration curve ranges from 0 to infinity after administration (AUC0-∞)

    The area under the time-concentration curve ranges from 0 to infinity after administration (AUC0-∞).

    Time frame: Day1-7 of cycle1 and cycle 4 : 0 hour pre-dose, 0,1, 2, 4, 8, 24, 48, 72, 144 hours after dose. Cycle1 Day15: 0 hour pre-dose. Day1 of cycle2 and 3 : 0 hour pre-dose. 0 hour after dose, Cycle4 Day15: 0 hour pre-dose. 28days as a cycle.

  12. Plasma drug half-life (T1/2)

    Plasma drug half-life

    Time frame: Day1-7 of cycle1 and cycle 4 : 0 hour pre-dose, 0,1, 2, 4, 8, 24, 48, 72, 144 hours after dose. Cycle1 Day15: 0 hour pre-dose. Day1 of cycle2 and 3 : 0 hour pre-dose. 0 hour after dose, Cycle4 Day15: 0 hour pre-dose. 28days as a cycle.

07

Study locations

2 of 7 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Nov 2026, 32 months after the start.

Of 69 industry-sponsored phase 2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 68. This study's planned 32 months is below that.

Counting every sponsor, half of 394 studies reached it within 57 months; a quarter within 35 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2025
First posted
Jan 10, 2025
StartActual
Mar 19, 2024
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Sep 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06767813
Responsible party
Sponsor
First posted
Jan 10, 2025
Start date
Mar 19, 2024
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Sep 19, 2025

Study contacts

Xianjun Yu, Doctor
Contact
yuxianjun@fudanpci.org
021-64175590

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868

Start the discussion